A novel composition from herbal extract (SCAP) alleviates skin severity and serum IgE level in NA/Nga mice, an atopic dermatitis model (55.17)

Abstract

Abstract Pimecrolimus (Elidel cream®) is an immunomodulating agent and is used for the treatment of atopic dermatitis (AD). However, it is reported that this treatment has side effects regarding the potential increased risk of lymph node or skin malignancy and is not sufficiently effective. SCAP is a composition of herb extracts from Sonchus oleraceus, Chelidonium majus var. asiaticum, Arctii Fructus, Portulacae Herba. which were traditionally used in oriental medicine as an analgesic, diuretic, and anti-inflammatory agents. The anti-atopic effect of SCAP was investigated in an atopic dermatitis animal model, NC/Nga mice. AD was induced by repeated application of 1-chloro 2, 4-dinitrobenzene (DNCB) in NC/Nga mice. And then mice were treated with SCAP or Pimecrolimus cream by dermal application. Scratching behavior, clinical skin severity, and the levels of total serum IgE were measured. After AD induction, scores of scratching behavior and clinical skin severity, and the levels of total serum IgE were increased. Treatment with SCAP significantly attenuated the scratching behavior and improved skin severity in a dose dependent manner in NC/Nga mice. Especially, treatment of SCAP 0.5 % reduced more rapidly scratching behavior, clinical skin severity, and the level of total serum IgE, compared to that of pimecrolimus cream. These results suggest that the SCAP may be an alternative substance for the treatment of AD.